ACADIA Pharmaceuticals Statistics

Total Valuation

ACADIA Pharmaceuticals has a market cap or net worth of GBP 2.50 billion. The enterprise value is 2.08 billion.

Market Cap	2.50B
Enterprise Value	2.08B

Important Dates

The next estimated earnings date is Thursday, February 27, 2025.

Earnings Date	Feb 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.65%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	108.95M

Valuation Ratios

The trailing PE ratio is 26.05.

PE Ratio	26.05
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	7.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.29, with an EV/FCF ratio of 13.77.

EV / Earnings	21.72
EV / Sales	2.79
EV / EBITDA	19.29
EV / EBIT	23.07
EV / FCF	13.77

Financial Position

The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.09.

Current Ratio	2.29
Quick Ratio	1.96
Debt / Equity	0.09
Debt / EBITDA	0.37
Debt / FCF	0.24
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 27.36% and return on invested capital (ROIC) is 13.41%.

Return on Equity (ROE)	27.36%
Return on Assets (ROA)	8.72%
Return on Invested Capital (ROIC)	13.41%
Return on Capital Employed (ROCE)	17.73%
Revenue Per Employee	1.12M
Profits Per Employee	154,642
Employee Count	598
Asset Turnover	1.15
Inventory Turnover	8.49

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-34.03%
50-Day Moving Average	17.41
200-Day Moving Average	16.42
Relative Strength Index (RSI)	58.25
Average Volume (20 Days)	2,167

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.86

Income Statement

In the last 12 months, ACADIA Pharmaceuticals had revenue of GBP 693.30 million and earned 95.88 million in profits. Earnings per share was 0.58.

Revenue	693.30M
Gross Profit	434.27M
Operating Income	83.74M
Pretax Income	101.99M
Net Income	95.88M
EBITDA	92.92M
EBIT	83.74M
Earnings Per Share (EPS)	0.58

Full Income Statement

Balance Sheet

The company has 421.79 million in cash and 36.83 million in debt, giving a net cash position of 384.96 million.

Cash & Cash Equivalents	421.79M
Total Debt	36.83M
Net Cash	384.96M
Net Cash Per Share	n/a
Equity (Book Value)	430.63M
Book Value Per Share	2.59
Working Capital	331.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 151.25 million and capital expenditures -52,227, giving a free cash flow of 151.20 million.

Operating Cash Flow	151.25M
Capital Expenditures	-52,227
Free Cash Flow	151.20M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 62.64%, with operating and profit margins of 12.08% and 13.83%.

Gross Margin	62.64%
Operating Margin	12.08%
Pretax Margin	14.71%
Profit Margin	13.83%
EBITDA Margin	13.40%
EBIT Margin	12.08%
FCF Margin	21.81%

Dividends & Yields

ACADIA Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.65%
Shareholder Yield	-1.65%
Earnings Yield	3.84%
FCF Yield	6.05%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ACADIA Pharmaceuticals has an Altman Z-Score of 3.53.

Altman Z-Score	3.53
Piotroski F-Score	n/a